Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
PLUVICTO Inj Lös 1000 MBq/ml Durchstf
Drug
Pluvicto, Injektions-/Infusionslösung
metastasiertem Prostatakrebs, Kastrationsresistenz, PSMA-Positiv
17.02. – radiotherapeuticals
HAM – Human medicine
LSIN – solution for injection/infusion
R – radiopharmaceutic products
A – Dispensed once only on prescription by a physician or veterinarian (A)
Z – approved
2/24/2023
2/23/2028
Dosage strength
Pluvicto 1000 MBq/ml, Injektions-/Infusionslösung
metastasiertem Prostatakrebs, Kastrationsresistenz, PSMA-Positiv
01
Z – approved
Package
7680686840010
In trade from / since 2/24/2023
A/R – Authorised / referenced
1 vial(s)
001
Z – approved
Declaration
Component
1000 MBq lutetium(177-Lu) vipivotidum tetraxetanum
acidum aceticum
natrii acetas
acidum gentisicum
natrii ascorbas
acidum penteticum
aqua ad iniectabile
7.1 mg natrium
natrii acetas
acidum gentisicum
natrii ascorbas
acidum penteticum
aqua ad iniectabile
7.1 mg natrium
Authorisation holder
7601001300477
Novartis Pharma Schweiz AG
6343 Risch (ZG)
6343 Risch (ZG)
Date of revision of the text
4/29/2025
Please log in as a company employee using your SIMIS-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.